These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20160166)

  • 1. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.
    Will B; Siddiqi T; Jordà MA; Shimamura T; Luptakova K; Staber PB; Costa DB; Steidl U; Tenen DG; Kobayashi S
    Blood; 2010 Apr; 115(14):2901-9. PubMed ID: 20160166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
    Rubert J; Qian Z; Andraos R; Guthy DA; Radimerski T
    BMC Cancer; 2011 Jan; 11():24. PubMed ID: 21247487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells.
    Wang H; Yang YB; Shen HM; Gu J; Li T; Li XM
    PLoS One; 2012; 7(12):e52483. PubMed ID: 23285061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
    Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S; Dai Y; Pei XY; Grant S
    Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression.
    Lutz C; Mozaffari M; Tosevski V; Caj M; Cippà P; McRae BL; Graff CL; Rogler G; Fried M; Hausmann M
    Clin Exp Immunol; 2015 Aug; 181(2):343-56. PubMed ID: 25845418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome.
    Niss O; Sholl A; Bleesing JJ; Hildeman DA
    J Allergy Clin Immunol; 2015 Mar; 135(3):762-70. PubMed ID: 25174872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
    Albershardt TC; Salerni BL; Soderquist RS; Bates DJ; Pletnev AA; Kisselev AF; Eastman A
    J Biol Chem; 2011 Jul; 286(28):24882-95. PubMed ID: 21628457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.
    Pandey MK; Gowda K; Doi K; Sharma AK; Wang HG; Amin S
    PLoS One; 2013; 8(11):e78570. PubMed ID: 24223823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
    Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
    J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
    Deng J; Carlson N; Takeyama K; Dal Cin P; Shipp M; Letai A
    Cancer Cell; 2007 Aug; 12(2):171-85. PubMed ID: 17692808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
    Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
    Hauck P; Chao BH; Litz J; Krystal GW
    Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PUMA and BIM are required for oncogene inactivation-induced apoptosis.
    Bean GR; Ganesan YT; Dong Y; Takeda S; Liu H; Chan PM; Huang Y; Chodosh LA; Zambetti GP; Hsieh JJ; Cheng EH
    Sci Signal; 2013 Mar; 6(268):ra20. PubMed ID: 23532334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
    Waibel M; Solomon VS; Knight DA; Ralli RA; Kim SK; Banks KM; Vidacs E; Virely C; Sia KC; Bracken LS; Collins-Underwood R; Drenberg C; Ramsey LB; Meyer SC; Takiguchi M; Dickins RA; Levine R; Ghysdael J; Dawson MA; Lock RB; Mullighan CG; Johnstone RW
    Cell Rep; 2013 Nov; 5(4):1047-59. PubMed ID: 24268771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells.
    Zeuner A; Pedini F; Francescangeli F; Signore M; Girelli G; Tafuri A; De Maria R
    Blood; 2009 Feb; 113(7):1522-5. PubMed ID: 19060244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.